Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H14O3.H2O |
| Molecular Weight | 260.2851 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC(C(O)=O)C1=CC(OC2=CC=CC=C2)=CC=C1
InChI
InChIKey=ARCKLGNSWQIPLI-UHFFFAOYSA-N
InChI=1S/C15H14O3.H2O/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2-11H,1H3,(H,16,17);1H2
DescriptionSources: http://www.drugbank.ca/drugs/DB00573Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Sources: http://www.drugbank.ca/drugs/DB00573
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/fenoprofen.html
Fenoprofen is a propionic acid derivative with analgesic, antiinflammatory and antipyretic properties. Fenoprofen inhibits prostaglandin synthesis by decreasing the enzyme needed for biosynthesis. In patients with rheumatoid arthritis, the anti-inflammatory action of fenoprofen has been evidenced by relief of pain, increase in grip strength, and reductions in joint swelling, duration of morning stiffness, and disease activity (as assessed by both the investigator and the patient). In patients with osteoarthritis, the anti-inflammatory and analgesic effects of fenoprofen have been demonstrated by reduction in tenderness as a response to pressure and reductions in night pain, stiffness, swelling, and overall disease activity (as assessed by both the patient and the investigator). These effects have also been demonstrated by relief of pain with motion and at rest and increased range of motion in involved joints. In patients with rheumatoid arthritis and osteoarthritis, clinical studies have shown fenoprofen to be comparable to aspirin in controlling the aforementioned measures of disease activity, but mild gastrointestinal reactions (nausea, dyspepsia) and tinnitus occurred less frequently in patients treated with fenoprofen than in aspirin-treated patients. It is not known whether fenoprofen causes less peptic ulceration than does aspirin. In patients with pain, the analgesic action of fenoprofen has produced a reduction in pain intensity, an increase in pain relief, improvement in total analgesia scores, and a sustained analgesic effect. Indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Also for the relief of mild to moderate pain.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL230 Sources: http://www.drugbank.ca/drugs/DB00573 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
|||
| Primary | NALFON Approved UseNALFON is a nonsteroidal anti-inflammatory drug indicated for:
• Relief of mild to moderate pain in adults.
• Relief of the signs and symptoms of rheumatoid arthritis.
• Relief of the signs and symptoms of osteoarthritis. Launch Date1976 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
28.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
105.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/501526/ |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
FENOPROFEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
Disc. AE: Reaction gastrointestinal, Reaction skin... Other AEs: Dyspepsia, Nausea... AEs leading to discontinuation/dose reduction: Reaction gastrointestinal (2%) Other AEs:Reaction skin (1%) Cardiovascular disorder (NOS) (0.5%) Dyspepsia (10%) Sources: Nausea (7.7%) Constipation (7%) Vomiting (2.6%) Abdominal pain (2%) Diarrhea (1.8%) Headache (8.7%) Somnolence (8.5%) Dizziness (6.5%) Tremor (2.2%) Confusion (1.4%) Sweating increased (4.6%) Pruritus (4.2%) Rash (3.7%) Tinnitus (4.5%) Blurred vision (2.2%) Hearing decreased (1.6%) Palpitations (2.5%) Nervousness (5.7%) Asthenia (5.4%) Peripheral edema (5%) Dyspnea (2.8%) Fatigue (1.7%) Upper respiratory infection (1.5%) Nasopharyngitis (1.2%) Gastritis (<1%) Ulcer peptic with perforation (<1%) Ulcer peptic with perforation (<1%) Gastrointestinal hemorrhage (<1%) Anorexia (<1%) Flatulence (<1%) Dry mouth (<1%) Blood in stool (<1%) Alkaline phosphatase increased (<1%) LDH increased (<1%) SGOT increased (<1%) Jaundice (<1%) Cholestatic hepatitis (<1%) Buccal mucosa aphthous ulceration (<1%) Taste metallic (<1%) Pancreatitis (<1%) Atrial fibrillation (<1%) Pulmonary edema (<1%) Electrocardiogram change (<1%) Supraventricular tachycardia (<1%) Renal failure (<1%) Dysuria (<1%) Cystitis (<1%) Hematuria (<1%) Oliguria (<1%) Azotemia (<1%) Anuria (<1%) Nephritis interstitial (<1%) Nephrosis (<1%) Acute papillary necrosis (<1%) Angioedema (<1%) Purpura (<1%) Bruising (<1%) Hemorrhage (<1%) Thrombocytopenia (<1%) Hemolytic anemia (<1%) Aplastic anemia (<1%) Agranulocytosis (<1%) Pancytopenia (<1%) Depression (<1%) Disorientation (<1%) Seizures (<1%) Trigeminal neuralgia (<1%) Burning tongue (<1%) Diplopia (<1%) Optic neuritis (<1%) Exfoliative dermatitis (<1%) Toxic epidermal necrolysis (<1%) Stevens-Johnson syndrome (<1%) Alopecia (<1%) Anaphylaxis (<1%) Urticaria (<1%) Malaise (<1%) Insomnia (<1%) Tachycardia (<1%) Personality change (<1%) Lymphadenopathy (<1%) Mastodynia (<1%) Fever (<1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiovascular disorder (NOS) | 0.5% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction skin | 1% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nasopharyngitis | 1.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Confusion | 1.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Upper respiratory infection | 1.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hearing decreased | 1.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fatigue | 1.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diarrhea | 1.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspepsia | 10% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Abdominal pain | 2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Reaction gastrointestinal | 2% Disc. AE |
400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blurred vision | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tremor | 2.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Palpitations | 2.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Vomiting | 2.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dyspnea | 2.8% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Rash | 3.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pruritus | 4.2% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tinnitus | 4.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Sweating increased | 4.6% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Peripheral edema | 5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Asthenia | 5.4% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nervousness | 5.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dizziness | 6.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Constipation | 7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nausea | 7.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Somnolence | 8.5% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Headache | 8.7% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Acute papillary necrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Agranulocytosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alkaline phosphatase increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Alopecia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anaphylaxis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Angioedema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anorexia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Anuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Aplastic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Atrial fibrillation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Azotemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Blood in stool | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Bruising | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Buccal mucosa aphthous ulceration | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Burning tongue | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cholestatic hepatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Cystitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Depression | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Diplopia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Disorientation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dry mouth | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Dysuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Electrocardiogram change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Exfoliative dermatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Fever | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Flatulence | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Gastrointestinal hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hematuria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemolytic anemia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Hemorrhage | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Insomnia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Jaundice | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| LDH increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Lymphadenopathy | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Malaise | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Mastodynia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephritis interstitial | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Nephrosis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Oliguria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Optic neuritis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancreatitis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pancytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Personality change | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Pulmonary edema | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Purpura | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Renal failure | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| SGOT increased | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Seizures | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Stevens-Johnson syndrome | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Supraventricular tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Tachycardia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Taste metallic | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Thrombocytopenia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Toxic epidermal necrolysis | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Trigeminal neuralgia | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Ulcer peptic with perforation | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
| Urticaria | <1% | 400 mg 3 times / day steady, oral Recommended Dose: 400 mg, 3 times / day Route: oral Route: steady Dose: 400 mg, 3 times / day Sources: |
unhealthy n = 6786 Health Status: unhealthy Condition: rheumatoid arthritis| osteoarthritis Population Size: 6786 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Agranulocytosis associated with fenoprofen. | 1979 Jun 22 |
|
| [Study on the release mechanism of fenoprofen calcium from hydrophillic sustained-release matrix]. | 2001 Jan |
|
| [Chiral separation by capillary electrochromatography on stationary phase adsorbed with protein]. | 2001 Sep |
|
| Prediction of selectivity for enantiomeric separations of uncharged compounds by capillary electrophoresis involving dual cyclodextrin systems. | 2002 Mar 1 |
|
| Renal papillary necrosis. | 2002 Nov-Dec |
|
| Quadrupole time-of-flight versus triple-quadrupole mass spectrometry for the determination of non-steroidal antiinflammatory drugs in surface water by liquid chromatography/tandem mass spectrometry. | 2003 |
|
| Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, Canada. | 2003 Dec |
|
| Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography-tandem mass spectrometry. | 2003 Dec 22 |
|
| Enhancement of selectivity and resolution in the enantioseparation of uncharged compounds using mixtures of oppositely charged cyclodextrins in capillary electrophoresis. | 2003 Jan |
|
| Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. | 2003 Jun 2 |
|
| Hyaluronidase inhibitors (sodium cromoglycate and sodium auro-thiomalate) reduce the local tissue damage and prolong the survival time of mice injected with Naja kaouthia and Calloselasma rhodostoma venoms. | 2003 Nov |
|
| Capillary electrophoresis with laser induced-fluorescence detection of profens derivatized with the water-soluble fluorogenic reagent 4-N-(4-N'-aminoethyl)piperazino-7-nitro-2,1,3-benzoxadiazole. | 2003 Sep 5 |
|
| Optimization of sample stacking for the simultaneous determination of nonsteroidal anti-inflammatory drugs with a wall-coated histidine capillary column. | 2004 Feb |
|
| Application of capillary electrophoresis with different sample stacking strategies for the determination of a group of nonsteroidal anti-inflammatory drugs in the low microg x L(-1) concentration range. | 2004 Feb |
|
| Effects of non-ionic surfactants on isotachophoretic separations of 2-arylpropionic acids. | 2005 Aug 19 |
|
| Synthesis of fenoprofen and gemfibrozil styrene-maleic acid copolymer conjugates. | 2005 Jun |
|
| Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. | 2005 Nov |
|
| Optimization of gas chromatographic method for the enantioseparation of arylpropionic non-steroidal anti-inflammatory drug methyl esters. | 2005 Sep 15 |
|
| The inflammatory process of gout and its treatment. | 2006 |
|
| Antioxidant activity and inhibition of human neutrophil oxidative burst mediated by arylpropionic acid non-steroidal anti-inflammatory drugs. | 2006 Aug |
|
| Vancomycin as chiral selector for enantioselective separation of selected profen nonsteroidal anti-inflammatory drugs in capillary liquid chromatography. | 2006 Aug |
|
| Interaction of ibuprofen and other structurally related NSAIDs with the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8). | 2006 Jun |
|
| Pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus. | 2006 Nov |
|
| Pharmaceutical chemicals and endocrine disrupters in municipal wastewater in Tokyo and their removal during activated sludge treatment. | 2006 Oct |
|
| Seasonality effects on pharmaceuticals and s-triazine herbicides in wastewater effluent and surface water from the Canadian side of the upper Detroit River. | 2006 Sep |
|
| The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. | 2007 Apr 1 |
|
| Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. | 2007 Jan |
|
| Synthesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. | 2007 Jan |
|
| A peripatetic pediatrician's journey into pediatric rheumatology: Part II. | 2007 Jun 21 |
|
| Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial-STORM STUDY. | 2007 Mar |
|
| Rapid online-SPE-MS/MS method for ketoprofen determination in dermal interstitial fluid samples from rats obtained by microdialysis or open-flow microperfusion. | 2007 May 1 |
|
| Stereoselective disposition of fenoprofen in plasma and synovial fluid of patients with rheumatoid arthritis. | 2007 May 5 |
|
| Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. | 2007 Nov |
|
| Removal of selected pharmaceuticals by chlorination, coagulation-sedimentation and powdered activated carbon treatment. | 2008 |
|
| Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. | 2008 |
|
| Efficient, selective, and green: catalyst tuning for highly enantioselective reactions of ethylene. | 2008 Apr 17 |
|
| A combination of statistical and analytical evaluation methods as a new optimization strategy for the quantification of pharmaceutical residues in sewage effluent. | 2008 Apr 21 |
|
| Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans. | 2008 Jul |
|
| Using subcritical/supercritical fluid chromatography to separate acidic, basic, and neutral compounds over an ionic liquid-functionalized stationary phase. | 2009 Apr 17 |
|
| The novel phosphoramidate derivatives of NSAID 3-hydroxypropylamides: synthesis, cytostatic and antiviral activity evaluations. | 2009 Jan |
|
| Synthesis of dehydroabietic acid-modified chitosan and its drug release behavior. | 2009 Jan 5 |
|
| Antioxidant activity of NSAID hydroxamic acids. | 2009 Jun |
|
| Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. | 2009 Sep |
|
| The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. | 2010 |
|
| PPARs in Irradiation-Induced Gastrointestinal Toxicity. | 2010 |
|
| Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north China. | 2010 Jul 15 |
|
| A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. | 2010 Jul 8 |
|
| Cyclooxygenase Inhibitors, Aspirin and Ibuprofen, Inhibit MHC-restricted Antigen Presentation in Dendritic Cells. | 2010 Jun |
|
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | 2010 Mar |
|
| Use of a robust dehydrogenase from an archael hyperthermophile in asymmetric catalysis-dynamic reductive kinetic resolution entry into (S)-profens. | 2010 May 5 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71316728
Created by
admin on Sat Dec 16 02:14:12 GMT 2023 , Edited by admin on Sat Dec 16 02:14:12 GMT 2023
|
PRIMARY | |||
|
1794827-48-7
Created by
admin on Sat Dec 16 02:14:12 GMT 2023 , Edited by admin on Sat Dec 16 02:14:12 GMT 2023
|
PRIMARY | |||
|
7MBN1TF74B
Created by
admin on Sat Dec 16 02:14:12 GMT 2023 , Edited by admin on Sat Dec 16 02:14:12 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
